etmf A Regulators Perspective Paula Walker, GCP Operations Manager & Senior GCP Inspector

Similar documents
Reflection paper on GCP compliance in relation to trial master files (paper and/or electronic) for management, audit and inspection of clinical trials

Inspections: an academic perspective

NEWCASTLE CLINICAL TRIALS UNIT STANDARD OPERATING PROCEDURES

Agenda. 16:00 16:10 Velkommen 16:10 16:15 Inspektion, hvad er det?

Good Clinical Practice (GCP): how does a laboratory that supports a clinical trial ensure compliance with these Regulations

GCP Basics - refresher

The European Medicines Agency Inspections ANNEX IV TO PROCEDURE FOR CONDUCTING GCP INSPECTIONS REQUESTED BY THE EMEA:

STANDARD OPERATING PROCEDURE

Standard Operating Procedure for Archiving

COMPUTER SYSTEMS VALIDATION

Author Signature: Date: 10 October 2017 The author is signing to confirm the technical content of this document

5 th Training Workshop for Micro-, Small- and Medium- Sized Enterprises (SMEs)

Data Integrity in Clinical Trials the Sponsor Perspective

Quality Site Visit Report FGK Clinical Research (FGK) GmbH, Munich Germany. Audit No. CT6018. Date of Audit: 3rd to 5th May 2017

Audit and Regulatory Inspection Nopanan Yaibuathes Clinical Research and Compliance Manager Roche Thailand Ltd.

STUDY CLOSURE AND ARCHIVING

EUROPEAN COMMISSION DIRECTORATE-GENERAL FOR HEALTH AND FOOD SAFETY. EudraLex. Volume 4

CUSTOMER AND SUPPLIER ROLES AND RESPONSIBILITIES FOR 21 CFR 11 COMPLIANCE ASSESSMENT. 21 CFR Part 11 FAQ. (Frequently Asked Questions)

Phlexglobal Whitepaper

GCP Inspections: Legal Basis

Good Clinical Practice

Points to Consider When Developing a TMF (Trial Master File) Strategy

etmf From Libraries of Paper to Electronic Filing Cabinets to Databases

Quality Assurance in Clinical Trials

Standard Operating Procedures (SOPs)

STANDARD OPERATING PROCEDURE SOP 310

ECTU Central Office SOP ECTU_TM_17 Management of Trial (IMP) Supplies

Reflection paper on guidance for laboratories that perform the analysis or evaluation of clinical trial samples

IMP Management and Accountability

The interface between Good Clinical Practice and Good Manufacturing Practice

EU Annex 11 US FDA 211, 820, 11; other guidelines Orlando López 11-MAY-2011

Audit Program Background Definition Management Example Content Risk assessment approach

1.4 Applicable Regulatory Requirement(s) Any law(s) and regulation(s) addressing the conduct of clinical trials of investigational products.

Brussels, C(2017) 8179 final. Guidelines

Quality Assurance of Investigational Medicinal Products. Sue McKenzie PPQA (A)

Guideline on good pharmacovigilance practices (GVP)

INSPECTION OF INDEPENDENT ETHICS COMMITTEES (IEC) The Italian Experience

Guideline on good pharmacovigilance practices (GVP)

Quality Assurance QA STANDARD OPERATING PROCEDURE FOR FDA or Pharmaceutical Sponsored Audits

The APIC Audit Programme Version 3, August 2010

White paper: Code of GMP Chapter 4 Documentation - PIC/S versus EU

R&D Manager Hillingdon Hospital. Revision History Effective Date Reason For Change. recommendations Version no:

Constructing an etmf 12/2/2011. consider your current etmf structure!! The do s and don ts of EDM. Disclaimer

EU Clinical Trial Regulation A view from the Industry

EUROPEAN COMMISSION ENTERPRISE DIRECTORATE-GENERAL QUESTIONS. and ANSWERS

Agenzia Italiana del Farmaco

Quality Audit Report. Name of Auditee Auditee Address. Audit No. CT 5500

Study Files and Filing

Trial oversight SOP for HEY-sponsored CTIMPs

Regulatory Requirements

References Concept. Principle. EU Annex 11 US FDA , (g), (i), 11 Orlando Lopez 2/15/11. Old Annex 11.

1 The Clinical Research Coordinator (CRC)... 1

Trial Master File / Investigator Site File Index Clinical Trials of Investigational Medicinal Products

The EFGCP Report on The Procedure for the Ethical Review of Protocols for Clinical Research Projects in Europe (Update: April 2011) Bulgaria

The APIC Audit Programme Version 5, July 2017

Quality Assurance for the Research Team: Connecting Day-to-Day Operations to a Regulatory Framework

Guidance for Industry - Computerized Systems Used in Clinical Trials

TABLE OF CONTENTS 1.0 INTRODUCTION...

ICH GCP E6(R2): Changes? Yes Challenges? Not as Difficult as You May Fear Lorrie D. Divers, President QRCP Solutions, Inc.

KINGSMANN CARE GROUP

STANDARD OPERATING PROCEDURE

PSMF in Practice Your Questions Answered! GPvP Symposium, 14 March 2014 Jonathan Rowell, Senior GPvP Inspector

Impact of the transposition of the European Clinical Trials Directive. CEMO, Paris 17 November 2004

New Pharmacovigilance legislation. Post-authorisation safety studies. ENCePP Plenary meeting. 3 May 2012

Intralinks Studyspace : Electronic Investigator-Controlled Site File (eisf)

Computer System Validation & Backup

Stephanie Gentilin, CCRA

Structural Assistance Act

Track III: International Clinical Trials: Global Compliance Norms and EU Focus

SAFETY MANAGEMENT SYSTEMS IMPLEMENTATION EVALUATION GUIDE

Safety Measures in the new Pharmacovigilance System

Computerised Systems. Alfred Hunt Inspector. Wholesale Distribution Information Day, 28 th September Date Insert on Master Slide.

What you missed at the 3 rd Trial Master File Summit January 28-29, Alexandria, VA.

Guideline on good pharmacovigilance practices (GVP)

GxP Auditing, Remediation, and Staff Augmentation

NHSLA Risk Management Standards for NHS Trusts Providing Community Services 2011/12

REGULATORY REQUIREMENTS FOR CLINICAL TRIAL APPROVAL MEDICAL DEVICES DR D DIALE MRS P NKAMBULE. 02 December 2015

TMF Reference Model. Topline results of 2014 TMF Survey #4. August 2014 Fran Ross TMF Survey Sub-team

Brexit Guidance for Stakeholders Human and veterinary medicines

Source Documents and Regulatory Binders October 6, 2016

CRO Outlook 2015: A Paperless Path to a Competitive Advantage

Ethics and Clinical trials EU approach

Records management policy. Document author Assured by Review cycle. Audit and Risk Committee. 1. Introduction Purpose or aim Scope...

GCP Refresher and GCP/GCDMP Trends. in the CTN. Denise King, MS, RD, CCRA & Lauren Yesko, BS. Presented by:

Human Research Protection Program Good Clinical Practice Guidance for Investigators Regulatory File Essential Documents

Clinical Research & ICH GCP E6(R2) (Basic / Refresher Training):

VOLUME 4 Good manufacturing practices ANNEX 13 Manufacture of investigational medicinal products JULY 2003

Pharmacovigilance Inspections Time to panic? Marie-Odile Hendrickx, DVM, MRCVS Pfizer Animal Health 13 December 2010

Trial Protocol. Version 1.2. Effective date: 18 May Dr Sarah Duggan, CTU Manager. V May 2010 Update web links.

EU Portal and Database Update

GxP Auditing, Remediation, and Quality System Resourcing

MHRA GDP Symposium. Novotel London West, London 8 & 10 December #GMDPevents

GxP Auditing, Remediation, and Staff Augmentation

Explanatory note on general fees payable to the European Medicines Agency

OPAC EN Operating Procedure for the Attestation of Conformity of Structural Bearings in compliance with Annex ZA of EN 1337/3/4/5/6/7

The EFGCP Report on The Procedure for the Ethical Review of Protocols for Clinical Research Projects in Europe (Update: April 2011) Ireland

Qualified Persons in the Pharmaceutical Industry. Code of Practice. March 2008

Impacto de las Nuevas Tendencias Regulatorias en la Producción de Parenterales. Innovacion en Packaging Primario

Good Documentation Practices. Documentation Requirements For Regulated Environments

Standard operating procedure

Transcription:

etmf A Regulators Perspective Paula Walker, GCP Operations Manager & Senior GCP Inspector

Agenda EU Legislation and Guidance News/Updates relating to TMF Structure and Content of e/tmf Inspecting etmfs GCP Findings for etmfs Critical Grading update by MHRA 2

Access to the etmf Is it possible for inspectors to access, directly, with reasonable notice, the etmf that is used by your employees? a) Yes b) No 3

Reference Documents EU Clinical Trials Directive 2001/20/EC (relating to the implementation of good clinical practice in the conduct of clinical trials on medicinal products for human use) EU GCP Directive: 2005/28/EC (laying down the principles and detailed guidelines for good clinical practice as regards investigational medicinal products for human use, as well as the requirements for authorisations of the manufacturing or importation of such products) into UK law. REGULATION (EU) No 536/2014 OF THE EUROPEAN PARLIAMENT AND OF THE COUNCIL of 16 April 2014 on clinical trials on medicinal products for human use, and repealing Directive 2001/20/EC Also Delegated and Implementing Acts

Reference Documents Recommendation on the content of the trial master file and archiving July 2006, Volume 10, Chapter V EMA/INS/GCP/636736/2012: Reflection paper on GCP compliance in relation to trial master files (paper and/or electronic) for management, audit and inspection of clinical trials EU GCP Inspectors Working Group - Subgroup NEW GUIDANCE March 2016 EMA GCP INSPECTORS Questions and Answers Important note: It has been decided that the revised version of the TMF document, based on the comments collected during the public consultation, will be incorporated into a guidance on TMF as part of the work related to the implementation of the new Clinical Trial Regulation (EU) 536/2014. A public consultation on the new guidance will follow in due course. CPMP/ICH/135/95: Note for Guidance on Good Clinical Practice (ICH E6) NEW ADDENDA

ICH E6 GCP Addenda All clinical trial information should be recorded, handled, and stored in a way that allows its accurate reporting, interpretation and verification. This principle applies to all records (paper or electronic) referenced in this guideline. The sponsor and investigator/institution should maintain a record of the location(s) of their respective essential documents. The storage system (irrespective of the media used) should provide for document identification, search and retrieval. Depending on the activities being carried out, individual trials may require additional documents not specifically mentioned in the essential document list. The sponsor and/or investigator/institution should include these as part of the trial master file. When a copy is used to replace an original document, the copy should fulfil the requirements for certified copies. Certified Copy - A paper or electronic copy of the original record that has been verified (e.g. by a dated signature) or has been generated through a validated process to produce an exact copy having all of the same attributes and information as the original. The investigator/institution should have control of all essential documents and records generated by the investigator/institution before, during and after the trial. The sponsor should ensure oversight of any trial-related duties and functions carried out on its behalf. http://www.ich.org/fileadmin/public_web_site/ich_products/guidelines/efficacy/e6/e6_r2 Addendum_Step2.pdf 6

Why is a Trial Master File Needed? Now. The verification of compliance with the standards of good clinical practice requires data, information and documents to be inspected, which means the competent authority conducting an official review of documents and records. [Directive 2001/20 EC] In the future Inspection means the act by a competent authority of conducting an official review of documents, facilities, records, quality assurance arrangements, and any other resources that are deemed by the competent authority to be related to the clinical trial and that may be located at the clinical trial site, at the sponsor's and/or contract research organisation's facilities, or at other establishments which the competent authority sees fit to inspect. [Regulation (EU) No 536/2014 (52)]

Why is a Trial Master File Needed? Now The trial master file shall provide the basis for the audit by the sponsor s independent auditor and for the inspection by the competent authority. [GCP Directive 2005/38/EC: Chapter 4 Article 16] In the future In order to be able to demonstrate compliance with the protocol and with this Regulation, a clinical trial master file, containing relevant documentation to allow effective supervision (monitoring by the sponsor and inspection by Member States), should be kept by the sponsor and by the investigator. [Regulation (EU) No 536/2014 (52)] The sponsor and the investigator shall keep a clinical trial master file. It shall be readily available, and directly accessible upon request, to the Member States. The clinical trial master file kept by the investigator and that kept by the sponsor may have a different content if this is justified by the different nature of the responsibilities of the investigator and the sponsor. [Regulation (EU) No 536/2014 Article 57] 8

Inspectors have a right of direct access to the TMF. Regulatory requirements are the same (and have always been the same) for paper and electronic TMF 9

The Content of the TMF Now the trial master file shall consist of essential documents, which enable both the conduct of a clinical trial and the quality of the data produced to be evaluated. Those documents shall show whether the investigator and the sponsor have complied with the principles and guidelines of good clinical practice [GCP Directive 2005/38/EC: Chapter 4 Article 16] In the future.the clinical trial master file shall at all times contain the essential documents relating to that clinical trial which allow verification of the conduct of a clinical trial and the quality of the data generated. [Regulation (EU) No 536/2014 Article 57] The sponsor of a clinical trial and the investigator shall ensure that the clinical trial is conducted in accordance with the protocol and with the principles of good clinical practice. [Regulation (EU) No 536/2014 Article 47] 10

Essential Documents Which one of these would you NOT regard as an essential document? a) Set of standard operating procedures used for the trial b) Code break envelopes c) An email from an investigator asking to clarify an eligibility criterion d) Annotated draft protocol following review by team member e) Project team meeting minutes f) Spreadsheet showing QC of statistical programming g) Completed test scripts for testing the build of an ecrf or IWRS h) Job descriptions of sponsor s staff involved in the trial i) All of the above are essential documents 11

Essential Documents Documents required to reconstruct the trial conduct to allow evaluation ICH/ Volume 10/ Essential Documents Documents not applicable or not required for the trial ICH - International Conference for Harmonisation 12

Essential Documents for a trial cannot be completely identified from a published guidance checklist. 13

Maintenance of the TMF EU Guidance (TMF 1, GCP 2 ) covers filing in a timely manner, indexing, use of electronic media etc. Essentially, during the trial and afterwards, the TMF should be up to date or complete, well structured, date ordered, indexed and documents in it should be complete, signed and dated (where applicable) and legible. 1. Recommendation on the content of the trial master file and archiving July 2006 2. CPMP/ICH/135/95: Note for Guidance on Good Clinical Practice (ICH E6) 14

Maintenance of the TMF Is your TMF? a) All paper b) One electronic system that contains all the trial essential documents c) Several electronic systems that between them contain all the trial essential documents d) A mixture of paper and at least one electronic system that between them contain all the trial essential documents e) Don t know 15

Maintenance of the Trial Master File Does your organisation have formal processes to define and maintain the TMF? a) Yes b) No 16

Maintenance of the Trial Master File 17

Electronic Trial Master File 18

Electronic Trial Master File Is filename useful- do I need a decoder document? Can they be sorted by DOCUMENT date? Is it the correct document when opened? Is the scanned image readable? Are these ALL the documents? Is the screen big enough to see document and the index? Can I tag/print a document to look at later? 19

Provision of the e/tmf for inspection For inspections of clinical trials, inspectors may require you to provide for inspection: Sponsor TMF relating to investigator sites (site Level), files with countryrelevant documentation (country level and trial level) Specific sections of the TMF or all of it (dependent upon the scope of the inspection) For contracted out trials (where TMF is managed by the CRO), the sponsor s oversight files may be required instead of/in addition to the CRO s TMF dependent upon inspection scope and trial status 20

Provision of TMF for Inspection What are the issues you face in providing the TMF (paper or electronic) to the inspectors? 21

Provision of TMF for inspection Direct Access is an inspector s right, however, issues with Hybrid TMF : Paper/ etmf; Formal etmf plus one or more electronic systems. Direct Access to primary etmf system or Paper Files is expected (often organisation s perception of what the TMF is). Access to a certified copy (sponsor would have to demonstrate that this is an accurate and reliable copy) may be acceptable to the inspector. Direct Access to other systems that contain TMF documents (often the organisation is unaware that these are part of the TMF) is expected. Access via a system user, access to a certified copy (sponsor would have to demonstrate that this is an accurate and reliable copy), or by specific document request may be acceptable to the inspector. 22

Provision of e/tmf for inspection The organisation should discuss the provision of the etmf (or specific sections) with the Lead Inspector when the inspection is being planned: Organisation should know what the e/tmf is and where all of its documents are located Should have formal processes to define, manage and control the e/tmf Should decide how the e/tmf will be provided to the inspector in accordance with the regulatory requirements Failure to meet the requirements agreed during the planning is NOT acceptable 23

Globalisation of Trial Functions Activities outside of UK, but involving UK Patient data (e.g. Data Management, Pharmacovigilance). Rights to see documentation, but scope of inspection may determine what is acceptable to the inspector: Actual TMF documents (direct access) Certified Copy of TMF documents Access to particular documents via document requests 24

TMF Review by Inspectors YOUR EXPERIENCE OF INSPECTION Inspectors browse through it all from start to finish in correct order? Inspectors browse particular sections of interest from start to finish? Inspectors have a list of documents they want to see and find them in the TMF? Inspectors request documents from TMF with a document request form? Inspectors ask someone to show them a document in the TMF? Inspectors mark up documents for later discussion? Inspectors use your SOPs to identify your quality records then find them in the TMF? Inspectors ask for documentation that you don t have in your TMF? 25

Inspection of etmf The TMF provided should be in the form as used by clinical operations staff/qa (especially if inspecting a live trial). Inspectors (auditors) should have direct read only access for an etmf and without reliance on a etmf super-user. etmf systems should : have an effective speed of access to view documents. be user friendly so inspectors do not need extensive training to use it (this could happen prior to inspection). GCP Inspectors do not have to sign any document (aside from site/facility access badges/sign in) at an inspection. GCP Inspectors are not required to follow organisation s SOPs/Policies relating to accessing the TMF. 26

Inspection of etmf An e-tmf should allow review in an efficient manner, analogous to that possible with paper TMFs i.e. review should not take longer. Ability to mark documents for later reference is valuable within an etmf ( yellow sticky equivalent). Access to the original paper records may be required. Review of validation processes/documentation and QC of an etmf etc. should be expected. 27

Moving to etmf Review all systems, processes and functional areas to assess location of all essential documents and data to ensure appropriate structural design for your organisation Ensure auditing/inspection needs are built into etmf functional requirements Piloting the system and initial paper filing to new structural inventories has been useful to organisations Risk based approach to migration of trials into the new etmf system New trials, Ongoing trials, Used in Submissions etc. 28

Inspection of e/tmf The provision of the TMF is your way to demonstrate compliance. Failure to provide the TMF in an appropriate way for MHRA domestic inspections will result in critical findings and potential further inspection days. For EMA inspections, if inspectors cannot assess compliance, this may mean the application for a MA is rejected. 29

Inspection outcome UK amended Critical finding definition: Where provision of the Trial Master File (TMF) does not comply with Regulation 31A 1-3, as the TMF is not readily available or accessible, or the TMF is incomplete to such an extent that it cannot form the basis of inspection and therefore impedes or obstructs inspectors carrying out their duties in verifying compliance with the Regulations 30

Common Inspection Findings Inadequate access to TMF, including: Organisation unable to provide full TMF (paper or electronic) for inspection; Paper/ Electronic hybrid impeded inspection (no clear index); TMF separated by functional groups dispersed over no. of systems without direct access; No inspector access to e.g. IMP, Data Management files located outside of the e TMF 31

Inspection findings continued.. Artificial TMF provided; System users unable to locate documents; QC checks insufficiently performed or documented; Incorrect documents uploaded to etmf; Poor file labelling; No process for archiving of electronic files; Inadequate equipment provided to inspectors for etmf review. 32

Summary Organisation s responsibility to meet regulatory requirements for provision of the e/tmf, failure to do so is likely to result in: Major/Critical findings Termination of inspection and revisit Additional days fees Whilst we appreciate there is a change from paper to electronic systems in clinical trials, compliance with regulatory requirements is still necessary at all times Inspectors aim to clarify and agree with organisation prior to the inspection, how and what will be required for the TMF inspection, however, during the inspection it may be necessary to change this dependent upon what is found. The commissioning of new etmf systems by an organisation should include regulatory requirements as part of the specification of the functional/user requirements. 33